Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz
Status:
Terminated
Trial end date:
2018-04-04
Target enrollment:
Participant gender:
Summary
This study evaluates whether there is an interaction between etonogestrel, the progestin
hormone released by the contraceptive implant Nexplanon, and efavirenz, a common medication
used to treat HIV. The endpoints measured in this study will help determine if such an
interaction leads to decreased contraceptive efficacy of the contraceptive implant.
Phase:
Phase 4
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
American College of Obstetricians and Gynecologists The Campbell Foundation